Halozyme (RV7) Stock Price & Analysis
RV7 Stock Chart & Stats
- Day’s Range
- EUR 114.05 - EUR 117.50
- 52-Week Range
- EUR 52.50 - EUR 118.40
- Previous Close
- EUR 117.45
- Volume
- N/A
- Average Volume (3M)
- 77
- Market Cap
- EUR 13.28B
- Enterprise Value
- EUR 11.40B
- Total Cash (Recent Filing)
- EUR 231.00M
- Total Debt (Recent Filing)
- EUR 2.15B
- Price to Earnings (P/E)
- 36.6
- Beta
- 0.31
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- 2.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Royalty Growth And Diversification
Rapid royalty growth across six commercial products supports a durable, asset-light revenue model. Diversification across established and newer launches can reduce dependence on any single therapy while expanding the recurring economics of ENHANZE over the next several quarters.
Strong Cash Generation
Exceptional cash conversion gives Halozyme substantial internal funding for research, partnerships, capital allocation, and debt management. Free cash flow close to net income also supports the quality of reported earnings and provides resilience as the company invests in future platforms.
Raised Outlook And Platform Expansion
The raised outlook and active deal cadence indicate continuing partner demand for Halozyme’s delivery technologies. ENHANZE expansion and Hypercon development could broaden the future product base, supporting revenue growth beyond currently commercialized products.
Bears Say
Patent Litigation Uncertainty
Active patent disputes create uncertainty around the timing and durability of future royalty streams tied to the contested technology. Adverse rulings, delays, or restrictions could affect commercial economics and require management attention across multiple jurisdictions.
Uneven Product Adoption
Adoption of newer subcutaneous products is important to sustaining Halozyme’s royalty growth, but conversion is not uniform across launches. Lower uptake can delay the expected revenue ramp, reduce partner enthusiasm, and make longer-term forecasts more dependent on a few successful products.
Leverage And Investment Pressure
Although current debt has fallen, the history of elevated leverage and capital-structure volatility reduces financial predictability. At the same time, higher operating investment could pressure margins if commercial growth slows, limiting flexibility while new platforms are developed.
Halozyme News
RV7 FAQ
What was Halozyme’s price range in the past 12 months?
What is Halozyme’s market cap?
When is Halozyme’s upcoming earnings report date?
How were Halozyme’s earnings last quarter?
Is Halozyme overvalued?
Does Halozyme pay dividends?
What is Halozyme’s EPS estimate?
How many shares outstanding does Halozyme have?
What happened to Halozyme’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Halozyme?
What is the TipRanks Smart Score and how is it calculated?
Halozyme Stock Smart Score
Company Description
Halozyme
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Helen I. Torley
- Employees
- 423
- Website
- www.halozyme.com
- Address
- 12390 El Camino Real, San Diego, CA, 92130, US
Halozyme (RV7) Earnings & Revenues
RV7 Company Deck
RV7 Earnings Call
Earnings Call SentimentPositive
The call communicated a strong operational and financial quarter with record revenue, robust royalty growth (+50% YoY), raised guidance, accelerated deal-making (five CLAs including expansion into ADCs and nucleic acids), and progress on Hypercon as a second platform. Key risks were emphasized around active patent litigation (Merck/Alteogen), increased operating investments (R&D/SG&A), conversion/uptake gaps for certain launches (e.g., OPDIVO conversion at 15% vs. target), and some execution/financing uncertainty around Hypercon manufacturing. On balance, the positive commercial momentum, durable high-margin royalty streams, substantial cash generation, and the pipeline/deal cadence significantly outweigh the legal and execution risks noted on the call.
View all DE:RV7 earnings summariesRV7 Net sales Breakdown
- 54.01% Royalties
- 36.28% Product sales
- 9.71% Revenues under collaborative agreements
RV7 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 6 |
| Technical Analysis | 2 | 2 | 6 |
| Moving Averages | 12 | 0 | 0 |
